Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
October 23, 2023
In times of mounting debt, the quest for universal health coverage (UHC) faces critical challenges. Rising debt has far-reaching effects, including reduced access to financing, political instability, and decreased spending on international aid. The burden of debt, coupled with high inflation, is thr...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...
Blog Post
July 06, 2023
USAID administrator Samantha Power’s aim to advance localization—with at least a quarter of funds going directly to local partners—has been widely lauded. A recent USAID report on localization indicates progress towards this goal, but major operational and contractual directions about how to impleme...
Blog Post
December 15, 2022
Dr. Yi-Chun Lo of Taiwan’s Centers for Disease Control and National Taiwan University Hospital joins Javier Guzman to discuss Taiwan’s COVID-19 experience and broader pandemic preparedness and response efforts. Together, they discuss the lessons Taiwan learned from previous outbreaks like SARS, succ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.